Survey Reveals Biotech Professionals' Attitude Toward New Business Models
A recent, free report, reveals biotech professionals' evaluations of potential business model alternatives for the future.
The following table shows the results of respondents' answers to the question: Given that some of the more traditional avenues to drug development could be facing problems, from the list below please indicate any change in your company’s stance or relative interest in using each drug development model/partner. As you will see from the following responses, choices varied greatly.
Source: Industry Standard Research, 2009.
You can view the full report here.
For more information on biotech, please see:
More Data Points:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
